Literature DB >> 11677707

Does the Birmingham model of oral anticoagulation management in primary care work outside trial conditions?

D A Fitzmaurice1, E T Murray, K M Gee, T F Allan.   

Abstract

The effectiveness of the Birmingham model of primary care oral anticoagulation management has previously been demonstrated within a randomised controlled trial. The aim of this study was to assess the effectiveness of the Birmingham model in routine care. All patients from 12 primary care centres attending either practice-based or hospital-based anticoagulation clinics were retrospectively followed up from October 1996 to March 1998. Outcome measures were therapeutic International Normalised Ratio (INR) control, haemorrhagic and thrombotic episodes, and recall frequency; 452 patients who had two or more INR results during the follow-up period were investigated. There were no significant differences between practice-based and hospital-based populations in terms of the percentage time in range, (69% and 64% respectively). The proportion of tests in range was significantly higher in the practice-based group (61% practice-based, 57% hospital-based; P = 0.015). There was no difference between the two populations in terms of mean follow-up time (36 days in each group). There were no significant differences between groups for the number of clinical outcomes per patient. This study confirmed that, within these practices, oral anticoagulation management is safe and effective using the Birmingham model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677707      PMCID: PMC1314129     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  7 in total

1.  Audit of anticoagulant therapy.

Authors:  P E Rose
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

2.  Monitoring anticoagulant control in general practice: comparison of management in areas with and without access to hospital anticoagulant.

Authors:  J P Pell; J Alcock
Journal:  Br J Gen Pract       Date:  1994-08       Impact factor: 5.386

3.  Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial.

Authors:  D A Fitzmaurice; F D Hobbs; E T Murray; R L Holder; T F Allan; P E Rose
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

4.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.

Authors:  F J van der Meer; F R Rosendaal; J P Vandenbroucke; E Briët
Journal:  Arch Intern Med       Date:  1993-07-12

6.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

7.  Evaluation of anticoagulant control in a pharmacist operated anticoagulant clinic.

Authors:  A S Radley; J Hall; M Farrow; P J Carey
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

  7 in total
  6 in total

Review 1.  A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation.

Authors:  D A Fitzmaurice; P Kesteven; K M Gee; E T Murray; R McManus
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

2.  Warfarin: almost 60 years old and still causing problems.

Authors:  Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

3.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study.

Authors:  Chris Burton; Chris Isles; John Norrie; Ruth Hanson; Elaine Grubb
Journal:  Br J Gen Pract       Date:  2006-09       Impact factor: 5.386

5.  Patient costs in anticoagulation management: a comparison of primary and secondary care.

Authors:  D Parry; S Bryan; K Gee; E Murray; D Fitzmaurice
Journal:  Br J Gen Pract       Date:  2001-12       Impact factor: 5.386

6.  External quality assessment for warfarin dosing using computerised decision support software.

Authors:  T P Oppenkowski; E T Murray; H Sandhar; D A Fitzmaurice
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.